The recent review by Pratoomsri et al 1 on the use of oxcarbazepine (OXC) in the treatment of bipolar disorder (BD) requires comment. The authors summarize case reports, retrospective chart reviews, open prospective studies, and double-blind studies reporting the efficacy and effectiveness of OXC in treating BD. Nevertheless, they fail to show the many biases in these reported studies. For example, they report the 2 double-blind, multicentre trials of 2 weeks' duration comparing OXC with haloperidol and lithium, respectively, in patients with acute mania. 2 Although OXC and the comparator drug were of equal efficacy in both studies, these studies were limited by relatively small sample sizes, lack of placebo control, and meager descriptions of study designs and outcomes. 3 Besides, in the study by Hummel et al, 4 the individual courses and scores of the Young Mania Rating Scale suggest a certain antimanic property of OXC only in patients with low-to-moderate manic episodes. Thus the usefulness of OXC monotherapy in severe mania appears doubtful.
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Other studies cited by Pratoomsri et al 1 show many limitations: methodological bias, small samples, insufficient follow-up periods, and confounding factors (patients concomitantly treated with several psychoactive drugs, for example, or different clinical profiles of enrolled patients). In other words, results may not be generalizable and should be interpreted cautiously.
Patients showed a percentage of dropouts due to hyponatremia, also when very small samples were considered, suggesting that this is probably a very common side effect; further, few patients were able to handle any more than 1500 to 1800 mg daily, which is about three-quarters of the rated maximum dosage. We have data showing that patients with severe or psychotic mania do not respond to OXC at all. A very recent multicentre trial showed that OXC is not significantly superior to placebo for the treatment of BD in children and adolescents. 5 OXC seems to benefit adults with clinically significant impulsive aggression and is effective and well-tolerated in refractory BD patients and schizoaffective disorder patients, but only as an add-on to concomitant therapies with mood stabilizers, antipsychotics, and antidepressives. Therefore, in 2006, there was still a lack of serious double-blind, placebo-controlled studies with sufficient samples of patients and adequate follow-up periods to confirm the efficacy and safety of OXC for the treatment of acute phases and maintenance of BD.
